Mark Chilvers

Employment

• BC Children's Hospital Research Institute Clinical Investigator
  2013 - Present
• BC Children's Hospital Director: Pediatric Respirologist & Cystic Fibrosis Clinic
  2008 - Present
• BC Children's Hospital Respiratory Fellow
  2003 - 2004

Education

• University of Leicester Bachelor of Medicine; Bachelor of Surgery - M.D.
  1988 - 1993
• University of Sheffield B.Sc. (Physiology)
  1985 - 1988

Projects & Funding

Projects & funding information is unavailable.

Publications (70)

• Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies
  Medrxiv 2025 DOI: 10.1101/2025.06.27.25330432
  +Save
• Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study
  European Respiratory Journal 2025 DOI: 10.1183/13993003.02435-2024
  +Save
• Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
  Lancet Respiratory Medicine 2025 DOI: 10.1016/S2213-2600(24)00411-9
  +Save
• A Germline Heterozygous Dominant Negative IKZF2 Variant Causing Syndromic Primary Immune Regulatory Disorder and ICHAD
  Journal of Clinical Immunology 2025 DOI: 10.1007/s10875-025-01882-2
  +Save
• Standards for the care of people with cystic fibrosis; establishing and maintaining health
  Journal of Cystic Fibrosis 2024 DOI: 10.1016/j.jcf.2023.12.002
  +Save
• High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification
  Human Genetics and Genomics Advances 2023 DOI: 10.1016/j.xhgg.2022.100156
  +Save
• Long-term respiratory outcomes following solid organ transplantation in children: A retrospective cohort study
  Pediatric Pulmonology 2022 DOI: 10.1002/ppul.25968
  +Save
• High Quality Phasing Using Linked-Read Whole Genome Sequencing of Patient Cohorts Informs Genetic Understanding of Complex Traits
  bioRxiv 2022 DOI: 10.1101/2022.03.28.486092
  +Save
• Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease
  npj Genomic Medicine 2022 DOI: 10.1038/s41525-022-00299-9
  +Save
• A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
  Journal of Cystic Fibrosis 2022 DOI: 10.1016/j.jcf.2022.02.003
  +Save